[Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Zeitschrift für Rheumatologie (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00393-005-0748-yPMID 15965816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.

  2005cited by this paper
• Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.

  2005cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

  2004cited by this paper
• Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis.

  2004cited by this paper
• Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis.

  2004cited by this paper
• The German etanercept registry for treatment of juvenile idiopathic arthritis

  2004cited by this paper
• Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study

  2003cited by this paper
• Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

  2003cited by this paper
• Natalizumab for active Crohn's disease.

  2003cited by this paper
• No association between human parvovirus B19 infection and Sjögren's syndrome.

  2003cited by this paper
• Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

  2002cited by this paper
• Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

  2002cited by this paper
• Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children.

  2002cited by this paper
• Etanercept therapy in children with treatment-resistant uveitis.

  2001cited by this paper
• Onset of multiple sclerosis associated with anti-TNF therapy

  2001cited by this paper
• Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis.

  2001cited by this paper
• Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.

  2001cited by this paper
• A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study

  2001cited by this paper
• Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis.

  2000cited by this paper
• A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• [Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee].

  2000cited by this paper
• Prognosis in children with rheumatic diseases: justification for consideration of new therapies.

  1999cited by this paper
• Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

  1998cited by this paper
• Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

  1998cited by this paper
• Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

  1993cited by this paper

• Kinder und Jugendliche mit Psoriasis

  2012cites this paper
• Therapie der Psoriasis im Kindes‐ und Jugendalter – ein deutscher Experten‐Konsens

  2011cites this paper
• Therapy of psoriasis in childhood and adolescence ‐ a German expert consensus

  2011cites this paper
• [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].

  2011cites this paper
• [Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].

  2010cites this paper
• [Articular diseases and uveitis].

  2008cites this paper
• Zur Behandlungsstrategie bei chronischer endogener Uveitis

  2007cites this paper
• [Options and strategy for the treatment of chronic endogenous uveitis].

  2007cites this paper
• Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists

  2006cites this paper
• Anti-TNF therapies in the management of acute and chronic uveitis.

  2006cites this paper
• Is there a relationship between juvenile idiopathic arthritis and periodontitis?

  2006cites this paper